Correction made after publication 2 September 2009: parenteral changed to non-parenteral in the title of the paper.
Successful treatment for refractory convulsive status epilepticus by non-parenteral lacosamide
Article first published online: 8 AUG 2009
Wiley Periodicals, Inc. © 2009 International League Against Epilepsy
Volume 51, Issue 2, pages 316–317, February 2010
How to Cite
Tilz, C., Resch, R., Hofer, T. and Eggers, C. (2010), Successful treatment for refractory convulsive status epilepticus by non-parenteral lacosamide. Epilepsia, 51: 316–317. doi: 10.1111/j.1528-1167.2009.02256.x
- Issue published online: 29 JAN 2010
- Article first published online: 8 AUG 2009
- Accepted June 1, 2009; Early View publication August 8, 2009.
- Convulsive status epilepticus;
- Refractory convulsive status epilepticus;
Lacosamide (Vimpat) is a newly licensed novel antiepileptic drug. We report a case of refractory convulsive status epilepticus (CSE) that was successfully controlled with lacosamide. The 38-year-old male patient was admitted for a series of complex partial seizures with secondary generalization leading to refractory CSE. During the transport to the hospital the patient was given 22.5 mg diazepam, 12.5 mg etomidate, and 5 mg midazolam without success. An additional dose of 4 mg lorazepam and a dose of 1,500 mg levetiracetam after admission were yet without clinical effect. A further treatment with lacosamide (300 mg via percutaneous gastric fistula) resulted in complete clinical remission of the epileptic activity within 30 min. The application of lacosamide resulted in cessation of CSE and was well tolerated. To our knowledge, this is the first case of successful treatment of refractory CSE with lacosamide. Further studies are needed to evaluate the safety and efficacy of lacosamide in treatment of SE.